62 related articles for article (PubMed ID: 17164579)
1. Effect of antiestrogens on EGF-mediated movement of human breast cancer cells.
Tong GM; Rajah TT; Zang XP; Bahr SJ; Pento JT
Pharmacology; 2007; 79(2):93-6. PubMed ID: 17164579
[TBL] [Abstract][Full Text] [Related]
2. The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells.
Tong GM; Rajah TT; Zang XP; Pento JT
Anticancer Res; 2002; 22(1A):103-6. PubMed ID: 12017270
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.
Chiarenza A; Lazarovici P; Lempereur L; Cantarella G; Bianchi A; Bernardini R
Cancer Res; 2001 Apr; 61(7):3002-8. PubMed ID: 11306479
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Treeck O; Haldar C; Ortmann O
Oncol Rep; 2006 Jan; 15(1):231-5. PubMed ID: 16328061
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Fan P; Wang J; Santen RJ; Yue W
Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
[TBL] [Abstract][Full Text] [Related]
6. Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.
Rajah TT; Pento JT
Cancer Invest; 1999; 17(1):10-8. PubMed ID: 10999044
[TBL] [Abstract][Full Text] [Related]
7. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor.
Cormier EM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Jan; 25(1):57-63. PubMed ID: 2784101
[TBL] [Abstract][Full Text] [Related]
8. Regulation of human estrogen receptor gene, epidermal growth factor receptor gene, and oncogenes by estrogen and antiestrogen in MCF-7 breast cancer cells.
Murayama Y; Kurata S; Mishim Y
Cancer Detect Prev; 1988; 13(2):103-7. PubMed ID: 3242819
[TBL] [Abstract][Full Text] [Related]
9. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells?
Czeczuga-Semeniuk E; Anchim T; Dziecioł J; Dabrowska M; Wołczyński S
Acta Biochim Pol; 2004; 51(3):733-45. PubMed ID: 15448735
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Joffroy CM; Buck MB; Stope MB; Popp SL; Pfizenmaier K; Knabbe C
Cancer Res; 2010 Feb; 70(4):1314-22. PubMed ID: 20145137
[TBL] [Abstract][Full Text] [Related]
11. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
[TBL] [Abstract][Full Text] [Related]
13. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Kallio A; Zheng A; Dahllund J; Heiskanen KM; Härkönen P
Apoptosis; 2005 Dec; 10(6):1395-410. PubMed ID: 16215679
[TBL] [Abstract][Full Text] [Related]
14. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
15. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
16. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
[TBL] [Abstract][Full Text] [Related]
17. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
[TBL] [Abstract][Full Text] [Related]
19. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Müller V; Jensen EV; Knabbe C
Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
[TBL] [Abstract][Full Text] [Related]
20. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
Lippman M; Bolan G; Huff K
Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
